Skip to main content
Clinical Trials/ISRCTN17105027
ISRCTN17105027
Completed
未知

Predicting vasovagal and other adverse events in Australian voluntary blood donors using a portable sensor that measures bio-signal data (PREVENT)

Australian Red Cross Lifeblood0 sites522 target enrollmentDecember 7, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Vasovagal/pre faint symptoms in voluntary whole blood and apheresis plasma donors
Sponsor
Australian Red Cross Lifeblood
Enrollment
522
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 7, 2021
End Date
May 16, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Eligible to donate as per the Australian Red Cross Lifeblood Guidelines for the Selection of Blood Donors
  • 2\. Donating whole blood or plasma for the first time
  • 3\. Willing and able to provide informed consent
  • 4\. Has a plasma or whole blood appointment at one of the participating donor centres (appointment made as a walk\-in donor or scheduled appointment)

Exclusion Criteria

  • 1\. Unwilling or unable to provide informed consent
  • 2\. Lack of understanding of the English language necessary to complete questionnaires. This study will not use translation services or interpreters
  • 3\. Contacted for a research study in the last 6 months as per Lifeblood contact policy
  • 4\. Donors with therapeutic, autologous, sample or platelet donation appointments
  • 5\. Lifeblood employees

Outcomes

Primary Outcomes

Not specified

Similar Trials